Tweet
Euro Surveill. 2018 Feb;23(7). doi: 10.2807/1560-7917.ES.2018.23.7.18-00057.
Interim effectiveness of trivalent influenza vaccine in a season dominated by lineage mismatched influenza B, northern Spain, 2017/18.
Castilla J1,2, Navascu?s A3, Casado I1,2, P?rez-Garc?a A3,1, Aguinaga A3, Ezpeleta G2, Pozo F4, Ezpeleta C3, Mart?nez-Baz I1,2, Primary Health Care Sentinel Network5, Network For Influenza Surveillance In Hospitals Of Navarre5.
Author information
Abstract
The 2017/18 interim estimate of trivalent influenza vaccine effectiveness (VE) was 39% (95% confidence interval: 20-54) in Navarre. Compared with individuals unvaccinated in the current and five previous seasons, VE against influenza B was 41% for current and any prior doses, 67% for current vaccination only, and 22% for any prior doses, and 43%, 51% and 54%, respectively against influenza A(H3N2). This suggests moderate VE despite predominance of lineage mismatched influenza B.
KEYWORDS:
case-control study; influenza; influenza vaccine; influenza-like illness; repeated vaccination; vaccine effectiveness
PMID: 29471624 DOI: 10.2807/1560-7917.ES.2018.23.7.18-00057
Interim effectiveness of trivalent influenza vaccine in a season dominated by lineage mismatched influenza B, northern Spain, 2017/18.
Castilla J1,2, Navascu?s A3, Casado I1,2, P?rez-Garc?a A3,1, Aguinaga A3, Ezpeleta G2, Pozo F4, Ezpeleta C3, Mart?nez-Baz I1,2, Primary Health Care Sentinel Network5, Network For Influenza Surveillance In Hospitals Of Navarre5.
Author information
Abstract
The 2017/18 interim estimate of trivalent influenza vaccine effectiveness (VE) was 39% (95% confidence interval: 20-54) in Navarre. Compared with individuals unvaccinated in the current and five previous seasons, VE against influenza B was 41% for current and any prior doses, 67% for current vaccination only, and 22% for any prior doses, and 43%, 51% and 54%, respectively against influenza A(H3N2). This suggests moderate VE despite predominance of lineage mismatched influenza B.
KEYWORDS:
case-control study; influenza; influenza vaccine; influenza-like illness; repeated vaccination; vaccine effectiveness
PMID: 29471624 DOI: 10.2807/1560-7917.ES.2018.23.7.18-00057